LivaNova plc (LIVN) Tops Q2 EPS by 15c, Revenues Beat; Updates FY20 EPS Mid-Point Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
LivaNova Reports Second Quarter 2020 Results
July 29, 2020 5:00 AM EDTLONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020.
For the second quarter of 2020, worldwide sales from continuing operations were $182.2 million, a decrease of 34.3 percent on a reported basis and a decline of 33.1 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), second quarter 2020 diluted loss per share from continuing operations was $1.81. Second quarter 2020 adjusted diluted loss per share from continuing operations was... More
